This site is intended only for healthcare professionals resident in the Republic of Ireland
The active substance in infliximab is a monoclonal antibody.1,2 A monoclonal antibody is an antibody (a type of protein) which recognises and binds to a specific structure (called an antigen) in the body1,2
The antigen that infliximab recognises is the cytokine (a messenger protein) tumour necrosis factor alpha (TNF-ɑ)1,2
Infliximab is a chimeric antibody, where the antigen-binding portion is of murine origin, whereas the constant region is of human origin3,4
TNF-alpha is involved in driving inflammation and is found at high levels in patients with the immune-mediated inflammatory diseases that infliximab is used to treat. By blocking TNF-ɑ, infliximab improves inflammation and other symptoms of those diseases1,2
Read about dosing and administration of INFLECTRA®
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023